IP
NAGE icon

Intellectus Partners’s Niagen Bioscience NAGE Stock Holding History

Intellectus Partners’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-2,000
Closed -$12K – 646
2017
Q4 		$12K Buy
+2,000
New +$10.8K ﹤0.01% 465

Other funds holding NAGE

IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $3.04B AUM 26.78% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Intellectus Partners's NAGE Position: Q1 2018 in Review

Intellectus Partners sold out of Niagen Bioscience (NAGE) in Q1 2018, closing a stake of 2,000 shares — an estimated $12K sold.

Intellectus Partners first reported a position in NAGE in Q4 2017 and held it in 1 quarter. The position peaked at $12K in Q4 2017. 58 funds tracked by Wall St. Rank hold NAGE as of Q1 2018.

  • Intellectus Partners reported no remaining Niagen Bioscience position as of Q1 2018 after selling out during the quarter.
  • Intellectus Partners sold 2,000 Niagen Bioscience shares in Q1 2018, an estimated $12K.
  • Intellectus Partners first reported a position in Niagen Bioscience in Q4 2017 and held it in 1 quarter.
  • Intellectus Partners's Niagen Bioscience position peaked at $12K in Q4 2017.
  • 58 funds tracked by Wall St. Rank held Niagen Bioscience as of Q1 2018.

Based on Intellectus Partners's 13F filing for Q1 2018, filed 15 May 2018.